Cannabidivarin (CBDV) vs. Placebo in Children with Autism Spectrum Disorder (ASD)

Brief description of study

The purpose of this study is to see if cannabidivarin (CBDV), is safe and able to improve symptoms of Autism Spectrum Disorder (ASD) in children. ASD is characterized by deficits in social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and high caregiver burden. The Center for Disease Control (CDC) currently estimates 1 in 68 children have Autism Spectrum Disorder (ASD). The current Food and Drug Administration (FDA) approved medications for symptoms of ASD are aripiprazole and risperidone, both of which are indicated for treating irritability in children with ASD. While the medications work well, they are can have side effects. There is a clear unmet need for new medicines to treat irritability in children with ASD that do not have the side effects of the currently approved treatments.


Clinical Study Identifier: s18-00206
ClinicalTrials.gov Identifier: NCT03202303
Principal Investigator: Orrin Devinsky.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.